Core Viewpoint - The company TianKang (301263.SZ) announced that its wholly-owned subsidiary, Shandong Huabo Kaisheng Biotechnology Co., Ltd., has received a drug registration certificate for Nimodipine Injection from the National Medical Products Administration of China [1] Company Summary - The registered product, Nimodipine Injection, is classified as a Class 4 chemical drug with a specification of 50ml: 10mg, and the marketing authorization holder is Shandong Huabo Kaisheng Biotechnology Co., Ltd. [1] - Nimodipine Injection is indicated for its anti-ischemic and anti-vasoconstrictive effects, which can improve blood circulation during the recovery phase of acute cerebrovascular diseases and after subarachnoid hemorrhage [1] Industry Summary - Currently, a total of 44 companies in China have obtained registration approval for this drug, indicating a competitive market landscape [1] - The future sales performance of Nimodipine Injection will be influenced by industry policies and market conditions, which introduces a level of uncertainty [1]
泰恩康：全资子公司收到尼莫地平注射液药品注册证书